July 7th 2025
Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Dr Joseph Alvarnas Discusses Clinical Risk in Value-Based Cancer Care
How Can Practices Seek Success With Oncology Payment Reform?
Preventing Chemotherapy-Associated Alopecia: A Case for Palliation?
Smoking Cessation Programs Need a Boost Under Medicaid Expansion